BAFF inhibition does not significantly impair immunization responses in patients with rheumatoid arthritis

Arthritis Research and Therapy

Volumn 17, Issue 1, 2015, Pages

  Bingham, Clifton O ^a   Winthrop, Kevin L ^b   Yang, Lili ^c   Lee, Chin ^c   Komocsar, Wendy J ^c  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B CELL ACTIVATING FACTOR; CD19 ANTIGEN; CD20 ANTIGEN; DIPHTHERIA PERTUSSIS TETANUS VACCINE; IMMUNOGLOBULIN G; METHOTREXATE; PLACEBO; PNEUMOCOCCUS VACCINE; TABALUMAB; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY;

ANTIBODY TITER; B LYMPHOCYTE; CONTROLLED STUDY; DOSAGE SCHEDULE COMPARISON; DRUG DOSE COMPARISON; HUMAN; IMMUNE RESPONSE; INFECTION RESISTANCE; LETTER; LOADING DRUG DOSE; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; PHASE 3 CLINICAL TRIAL (TOPIC); RHEUMATOID ARTHRITIS; VACCINATION; ADULT; AGED; ANTAGONISTS AND INHIBITORS; ARTHRITIS, RHEUMATOID; COMBINATION DRUG THERAPY; DOUBLE BLIND PROCEDURE; DRUG ADMINISTRATION; DRUG EFFECTS; FEMALE; IMMUNOLOGY; MALE; METABOLISM; MIDDLE AGED; PROCEDURES; RANDOMIZED CONTROLLED TRIAL; TIME FACTOR; TREATMENT OUTCOME;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ARTHRITIS, RHEUMATOID; B-CELL ACTIVATING FACTOR; B-LYMPHOCYTES; DIPHTHERIA-TETANUS-ACELLULAR PERTUSSIS VACCINES; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOGLOBULINS; IMMUNOSUPPRESSIVE AGENTS; LYMPHOCYTE COUNT; MALE; METHOTREXATE; MIDDLE AGED; TIME FACTORS; TREATMENT OUTCOME; VACCINATION;

EID: 84955389030     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/s13075-015-0867-z     Document Type: Letter

References (4)

1. Doran MF, Crowson CS, Pond GR, O'Fallon WM, Gabriel SE. Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum. 2002;46:2287-93. doi: 10.1002/art.10524.
2. Gelinck LB, van der Bijl AE, Visser LG, Huizinga TW, van Hogezand RA, Rijkers GT, et al. Synergistic immunosuppressive effect of anti-TNF combined with methotrexate on antibody responses to the 23 valent pneumococcal polysaccharide vaccine. Vaccine. 2008;26:3528-33. doi: 10.1016/j.vaccine.2008.04.028.
3. Manetta J, Bina H, Ryan P, Fox N, Witcher DR, Kikly K. Generation and characterization of tabalumab, a human monoclonal antibody that neutralizes both soluble and membrane-bound B-cell activating factor. J Inflamm Res. 2014;7:121-31. doi: 10.2147/JIR.S67751.
4. Smolen JS, Weinblatt ME, van der Heijde D, Rigby WF, van Vollenhoven R, Bingham CO, et al. Efficacy and safety of tabalumab, an anti-B-cell-activating factor monoclonal antibody, in patients with rheumatoid arthritis who had an inadequate response to methotrexate therapy: results from a phase III multicentre, randomised, double-blind study. Ann Rheum Dis. 2015;74(8):1567-70. doi: 10.1136/annrheumdis-2014-207090.